120 related articles for article (PubMed ID: 14760895)
1. The effect of number of mutations and of drug-class sparing on virological response to salvage genotype-guided antiretroviral therapy.
Ciancio BC; Trotta MP; Lorenzini P; Forbici F; Visco-Comandini U; Gori C; Bonfigli S; Bellocchi MC; Sette P; D'Arrigo R; Tozzi V; Zaccarelli M; Boumis E; Narciso P; Perno CF; Antinori A
Antivir Ther; 2003 Dec; 8(6):611-6. PubMed ID: 14760895
[TBL] [Abstract][Full Text] [Related]
2. Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome.
Tozzi V; Zaccarelli M; Bonfigli S; Lorenzini P; Liuzzi G; Trotta MP; Forbici F; Gori C; Bertoli A; Bellagamba R; Narciso P; Perno CF; Antinori A;
Antivir Ther; 2006; 11(5):553-60. PubMed ID: 16964822
[TBL] [Abstract][Full Text] [Related]
3. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up.
Clevenbergh P; Durant J; Halfon P; del Giudice P; Mondain V; Montagne N; Schapiro JM; Boucher CA; Dellamonica P
Antivir Ther; 2000 Mar; 5(1):65-70. PubMed ID: 10846595
[TBL] [Abstract][Full Text] [Related]
4. Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.
de la Rosa R; Ruíz-Mateos E; Rubio A; Abad MA; Vallejo A; Rivero L; Genebat M; Sánchez-Quijano A; Lissen E; Leal M
J Antimicrob Chemother; 2004 Jan; 53(1):95-101. PubMed ID: 14657091
[TBL] [Abstract][Full Text] [Related]
5. Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.
Harrigan PR; Hertogs K; Verbiest W; Larder B; Yip B; Brumme ZL; Alexander C; Tilley J; O'Shaughnessy MV; Montaner JS
Antivir Ther; 2003 Oct; 8(5):395-402. PubMed ID: 14640386
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients.
Clevenbergh P; Boulmé R; Kirstetter M; Dellamonica P
HIV Med; 2004 Jul; 5(4):284-8. PubMed ID: 15236618
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B
Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016
[TBL] [Abstract][Full Text] [Related]
8. The V118I mutation as a marker of advanced HIV infection and disease progression.
Zaccarelli M; Tozzi V; Lorenzini P; Forbici F; Narciso P; Ceccherini-Silberstein F; Trotta MP; Bertoli A; Liuzzi G; Marconi P; Mosti S; Perno CF; Antinori A
Antivir Ther; 2007; 12(2):163-8. PubMed ID: 17503658
[TBL] [Abstract][Full Text] [Related]
9. Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy.
Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Niubó J; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
Antivir Ther; 2012; 17(3):577-83. PubMed ID: 22301439
[TBL] [Abstract][Full Text] [Related]
10. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy.
Bossi P; Peytavin G; Ait-Mohand H; Delaugerre C; Ktorza N; Paris L; Bonmarchand M; Cacace R; David DJ; Simon A; Lamotte C; Marcelin AG; Calvez V; Bricaire F; Costagliola D; Katlama C
HIV Med; 2004 Sep; 5(5):352-9. PubMed ID: 15369510
[TBL] [Abstract][Full Text] [Related]
11. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
Bongiovanni M; Gianotti N; Chiesa E; Nasta P; Cicconi P; Capetti A; di Biagio A; Matti A; Tirelli V; Marconi P; de Luca A; Mussini C; Gatti F; Zaccarelli M; Abeli C; Torti C; Antinori A; Castagna A; d'Arminio Monforte A
Infection; 2007 Dec; 35(6):451-6. PubMed ID: 18034204
[TBL] [Abstract][Full Text] [Related]
12. Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations.
Bongiovanni M; Bini T; Adorni F; Meraviglia P; Capetti A; Tordato F; Cicconi P; Chiesa E; Cordier L; Cargnel A; Landonio S; Rusconi S; d'Arminio Monforte A
Antivir Ther; 2003 Jun; 8(3):209-14. PubMed ID: 12924537
[TBL] [Abstract][Full Text] [Related]
13. Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.
Torti C; Uccelli MC; Quiros-Roldan E; Gargiulo F; Tirelli V; Lapadula G; Regazzi M; Pierotti P; Tinelli C; De Luca A; Patroni A; Manca N; Carosi G
J Clin Virol; 2006 Apr; 35(4):414-9. PubMed ID: 16280255
[TBL] [Abstract][Full Text] [Related]
14. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
Joly V; Descamps D; Yeni P
AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
[TBL] [Abstract][Full Text] [Related]
15. Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation.
Antinori A; Trotta MP; Lorenzini P; Torti C; Gianotti N; Maggiolo F; Ceccherini-Silberstein F; Nasto P; Castagna A; De Luca A; Mussini C; Andreoni M; Perno CF;
Antivir Ther; 2007; 12(8):1175-83. PubMed ID: 18240858
[TBL] [Abstract][Full Text] [Related]
16. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
17. The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens.
Maggiolo F; Ripamonti D; Torti C; Arici C; Antinori A; Quiros-Roldan E; Minoli L; Sighinolfi L; Nasta P; Suter F;
Antivir Ther; 2006; 11(7):923-9. PubMed ID: 17302255
[TBL] [Abstract][Full Text] [Related]
18. The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine.
Sproat M; Pozniak AL; Peeters M; Winters B; Hoetelmans R; Graham NM; Gazzard BG
Antivir Ther; 2005; 10(2):357-61. PubMed ID: 15865231
[TBL] [Abstract][Full Text] [Related]
19. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
Delaugerre C; Peytavin G; Dominguez S; Marcelin AG; Duvivier C; Gourlain K; Amellal B; Legrand M; Raffi F; Costagliola D; Katlama C; Calvez V
J Med Virol; 2005 Nov; 77(3):345-50. PubMed ID: 16173015
[TBL] [Abstract][Full Text] [Related]
20. A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study.
Torti C; Quiros-Roldan E; Regazzi M; De Luca A; Mazzotta F; Antinori A; Ladisa N; Micheli V; Orani A; Patroni A; Villani P; Lo Caputo S; Moretti F; Di Giambenedetto S; Castelnuovo F; Maggi P; Tinelli C; Carosi G;
Clin Infect Dis; 2005 Jun; 40(12):1828-36. PubMed ID: 15909273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
